BNO 5.26% 20.0¢ bionomics limited

Ann: BNC105 Clinical Trial In Combination With Nivolumab, page-15

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 593 Posts.
    lightbulb Created with Sketch. 24
    We don't want get to get overly excited about the BMS joint trial. It has only been "kicked off". But, the good news is that it is a joint trial and there is more horsepower with BMS alongside than BNO trying to go it alone. Maybe this should be the model for BNO as it tries to re-build. GLTA
 
watchlist Created with Sketch. Add BNO (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.